ITX-0121 / Illudent - LARVOL DELTA

ITX-0121: A therapeutic strategy for transcription-coupled repair-deficient cancers. (ASCO 2025) - " We are comparing sensitivity of these daughter lines to our lead drug ITX-0121, as well as to other DNA damaging agents such as cisplatin. Thus, despite the administration of a cytotoxic agent, TC-NER deficient cancer patients can be treated at a non-toxic dose; if toxicity occurs, it should be limited to transient thrombocytopenia, as indicated by prior studies."

Oncology • Solid Tumor • Thrombocytopenia • ERCC2 • ERCC3 • ERCC4 • ERCC6

Analysis of the Genie database for TC-NER deficient cancers sensitive to ITX-0121 (AACR 2025) - "Toxicity (if it occurs) should be limited to transient thrombocytopenia based on prior studies. In summary, we are utilizing a Precision Medicine approach to develop a drug for an indication defined by a specific molecular alteration across cancer types, which in this case is the presence of TC-NER deficiency as identified by monoallelic mutations in specific genes coding for proteins in the TC-NER pathway."

Endocrine Cancer • Melanoma • Oncology • Solid Tumor • Thyroid Gland Carcinoma • ERCC1 • ERCC2 • ERCC5 • ERCC6